bryostatin-1


Also found in: Encyclopedia.

bryostatin-1

A drug with a unique action against cancer cells, that is being used in trials of treatment of leukaemia and malignant melanoma. Bryostatin is formed by a bacterium Endobugula sertula that parasitizes the boat-fouling marine animal Bugula neritina . The drug also shows promise as a stimulant of the immune system against breast cancer.
Mentioned in ?
References in periodicals archive ?
The complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1.
It was reported yesterday that the contract has been signed for an accelerated synthesis of Alzheimer's drug, bryostatin-1.
Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanism.
Bryostatin-1 has been shown to potently inhibit the growth and self-renewal capacity of human leukemia cells at nanomolar concentrations in vivo and in vitro (26-28).
Dual effects of bryostatin-1 on spatial memory and depression.
For example, Figure 3 shows a MALDI-MS analysis of a pentanol extract of sediment from the same ecosystem and illustrates peaks where bryostatin-1 plus [Na.
We have also discovered that bryostatin-1 synergizes with Histone Deacetylases (HDAC) inhibitors such as valproic acid to antagonise HIV-1 latency.
M2 EQUITYBITES-August 17, 2016-Neurotrope BioScience submits amended protocol for Phase two clinical trial of bryostatin-1 to US FDA
M2 PHARMA-August 17, 2016-Neurotrope BioScience submits amended protocol for Phase two clinical trial of bryostatin-1 to US FDA
Kortmansky and Schwartz (2003) reported that short-term exposure to bryostatin-1 activates PKC, whereas prolonged exposure promotes significant PKC down-regulation.
This activation and therapeutic response can be achieved by injecting bryostatin 1 directly into chronically inflamed tissues, treating the skin with bryostatin-1, or perfusing organs with bryostatin-1 prior to transplantation and cold storage.